Cartherics is pleased to announce that Dr Vera Evtimov, Project Manager and Principal Scientist, will be presenting her work in ovarian cancer research at the European Society for Medical Oncology Targeted Anticancer Therapies Congress, ESMO TAT 2023, in Paris this March.
ESMO TAT, known as “The Home of Phase I in Oncology”, is the leading […]
Cartherics is pleased to announce that Dr Madeline Cao, Research Fellow, will be presenting at Australia Biologics 2023 at Crown Promenade, Melbourne.
The Australia Biologics Festival 2023 is Australia’s premier conference that aims to gather the innovators, pioneers, leaders in the biologics fraternity including biologics, biosimilars, vaccines, cell and gene therapy (CGT) and evolving therapeutics […]
Cartherics to Present at Biotech Showcase™ 2023
Dr Ian Nisbet will provide a presentation on Cartherics’ technology and development program at Biotech Showcase, with a view to engaging with potential investors and partners
Melbourne, Australia, 22 December 2022 – Cartherics, a biotechnology company developing immune cell therapies for the treatment of cancer, announced today that it […]
Dr Ian Nisbet Chief Operating Officer
Held in partnership with Harvard Stem Cell Institute, this virtual one-day investor and partner conference will explore stem cell therapeutics in the areas of regenerative medicine, oncology and emerging academic research. It will also showcase cutting-edge science, industry trends and the commercial potential of this innovative sector to an invited […]
7th Innate Killer Summit (San Diego, California)
Cartherics Chief Development Officer, Dr Nicholas Boyd
The innate cell therapy field is exploding as novel research charges through the clinic, proving its potential as a safe, efficacious, and cost-effective treatment. From 30 March-1 April 2022 Pacific Daylight Time (PDT) industry experts will meet in San Diego, California to discuss […]
The 4th Allogeneic Cell Therapies Summit is the leading industry-dedicated meeting that considers pre-clinical development, translation, manufacturing, supply and storage of allogeneic cell therapies to improve the accessibility and efficacy of patient care worldwide.
400+ experts from pharma, biotech and leading academia are expected to attend in Boston, USA […]
Presentation at the Next Generation CAR-TCR Summit (London, UK)
Cartherics Chief Development Officer, Dr Nicholas Boyd
CAR-T immunotherapy has exploded over the last half a decade. It is now a billion-dollar market that is expanding rapidly with over 400+ new cell therapy trials in 2021 alone. But challenges still remain in solid tumours, toxicity management and manufacturing […]
Chief Development Officer, Dr Nicholas Boyd
Cell therapies have the potential to not only be life-saving but curative for a host of diseases. However, inherent limitations in autologous based CAR-T therapy face major roadblocks for mass adoption and therapeutic effects in solid tumour indications.
On Friday 28 January at 7:30 am AEDT Nicholas will discuss the design, […]
By Leigh Dayton
27 August 2021
Cartherics CEO Alan Trounson congratulates Natalia Benetti for her important research in developmental cell biology: “It’s great work and very well presented”.
The company also applauds the Australian Regenerative Medicine Institute for successfully organising the 13th Victorian State Conference of the […]
By Leigh Dayton
22 July 2021
Cartherics is delighted to announce that it is a sponsor of the Australia and New Zealand Society of Cell and Developmental Biology’s Victorian State Conference. The highly regarded one-day event is booked for 26 August at the University of Melbourne.
Cartherics CEO Alan Trounson welcomes the opportunity to support the meeting.
“It is […]
Cartherics’ mission is the development of novel, “off-the-shelf” (allogeneic) immune cell therapy products for the treatment of cancer.
Stay informed about our latest news and developments
© Copyright 2022 | Cartherics Pty ltd
